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Abstract
Background: Tumor vasculature frequently fails to supply sufficient levels of oxygen to tumor tissue resulting in
radioresistant hypoxic tumors. To improve therapeutic outcome radiotherapy (RT) may be combined with cytotoxic
agents.
Methods: In this study we have investigated the combination of RT with the cytotoxic agent doxorubicin (DXR)
encapsulated in pegylated liposomes (PL-DXR). The PL-DXR formulation Caelyx
® was administered to male mice
bearing human, androgen-sensitive CWR22 prostate carcinoma xenografts in a dose of 3.5 mg DXR/kg, in
combination with RT (2 Gy/day × 5 days) performed under normoxic and hypoxic conditions. Hypoxic RT was
achieved by experimentally inducing tumor hypoxia by clamping the tumor-bearing leg five minutes prior to and
during RT. Treatment response evaluation consisted of tumor volume measurements and dynamic contrast-
enhanced magnetic resonance imaging (DCE MRI) with subsequent pharmacokinetic analysis using the Brix model.
Imaging was performed pre-treatment (baseline) and 8 days later. Further, hypoxic fractions were determined by
pimonidazole immunohistochemistry of excised tumor tissue.
Results: As expected, the therapeutic effect of RT was significantly less effective under hypoxic than normoxic
conditions. However, concomitant administration of PL-DXR significantly improved the therapeutic outcome
following RT in hypoxic tumors. Further, the pharmacokinetic DCE MRI parameters and hypoxic fractions suggest
PL-DXR to induce growth-inhibitory effects without interfering with tumor vascular functions.
Conclusions: We found that DXR encapsulated in liposomes improved the therapeutic effect of RT under hypoxic
conditions without affecting vascular functions. Thus, we propose that for cytotoxic agents affecting tumor vascular
functions liposomes may be a promising drug delivery technology for use in chemoradiotherapy.
Background
During tumor growth abnormal tumor vasculature fre-
quently fails to supply sufficient levels of oxygen to tumor
tissue, resulting in various degrees of hypoxia [1,2]. Tumor
hypoxia is known to cause treatment resistance and to
promote metastatic disease progression [3-5]. To improve
radiotherapy (RT) efficacy of radioresistant tumors, several
approaches have been suggested [6,7]. One strategy is to
combine conventional cytotoxic agents with RT to
increase the therapeutic effects, i.e. chemoradiotherapy
(CRT) [8,9].
The anthracycline chemotherapeutic drug doxorubicin
(DXR) has been demonstrated to enhance the therapeutic
effect of RT [10-13], presumably by preventing cells from
repairing radiation-induced DNA damage [11-13]. DXR
has also reportedly enhanced the effect of RT under
experimental in vitro hypoxic conditions [14].
By encapsulating DXR in liposomes, DXR accumula-
tion in the heart is reduced, resulting in less cardiac toxi-
cities compared to conventional DXR [15,16]. Abnormal
tumor vasculature also favors accumulation of liposomes
due to the enhanced permeability retention effect [17].
Moreover, by incorporating polyethylene glycol (PEG) in
the liposomal membrane, clearance by the cells of the
reticulo-endothelial system is reduced, resulting in pro-
longed circulation time [18].
Liposomes accumulated in the tumor may act as depots
for sustainable drug release, making them particularly
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any medium, provided the original work is properly cited.beneficial during a course of CRT, since daily drug dos-
ing would be needless [19]. Moreover, as liposomes avoid
accumulation in healthy tissue, radiation enhancement
may primarily be located to tumors, reducing toxicities in
neighboring healthy tissues [19,20]. Pegylated liposomal
DXR (PL-DXR) has been shown to increase the effect of
RT in preclinical studies [19,21]. Promising results have
been demonstrated in clinical studies in sarcoma [20], as
well as in locally advanced non-small cell lung cancer
and head and neck cancer [22]. In prostate cancer,
anthracyclines as free doxorubicin and epirubicin alone
have shown to have a palliative effect on patients with
incurable, metastatic, hormone-refractory prostate cancer
[23]. However, according to our knowledge no clinical
investigations have reported on the combined use of
anthracyclines and RT. Recognizing the impact of tumor
hypoxia in prostate cancer disease progression and treat-
ment resistance [3], the combination of anthracyclines
with RT to increase radiosensitivity of hypoxic tumor
regions may represent a potential therapeutic strategy for
advanced prostate cancer.
The objective of this study was to evaluate the potential
therapeutic benefit of administering PL-DXR (Caelyx
®)
to tumor-bearing mice receiving RT under hypoxic,
radioresistant conditions. Therapy-mediated changes in
tumor vascular functions and tumor hypoxia were
assessed by dynamic contrast-enhanced magnetic reso-
nance imaging (DCE MRI) and pimonidazole immuno-
histochemistry, respectively.
Methods
Materials
The PL-DXR product Caelyx
® was supplied by the phar-
macy at the Norwegian Radium Hospital, Oslo, Norway
(European distributor; Schering-Plough). Pimonidazole
hydrochloride was supplied by Natural Pharmacia Interna-
tional, Inc., Burlington, MA, USA, and the contrast agent
Dotarem
® was from Laboratoire Guerbet, Paris, France.
Dako EnVision™+ System-HRP (DAB) was supplied by
Dako Corporation, DA, USA.
F o ra n a e s t h e s i ao fm i c eam i x t u r eo f2 . 4m g / m lt i l e t a m i n e
and 2.4 mg/ml zolazepam (Zoletil
® vet, Virbac Labora-
tories, Carros, France), 3.8 mg/ml xylazine (Narcoxyl
® vet,
Roche, Basel, Switzerland) and 0.1 mg/ml butorphanol
(Torbugesic
®, Fort Dodge Laboratories, Fort Dodge, IA,
USA) was prepared and used.
Experimental animals
M a l ea t h y m i cn u d eB a l b / cm i c ew e r ep r o v i d e db yt h e
Department of Comparative Medicine (animal facility),
Oslo University Hospital. The androgen-sensitive
CWR22 xenograft, originating from a human, primary
prostate carcinoma [24], was serially transplanted
between mice. In brief, by blunt dissection through a
skin incision tumor fragments (~2 × 2 × 2) mm
3 were
subcutaneously implanted on the upper leg (proximal to
the knee joint) of 4-5 weeks old mice. The skin incision
was sealed with topical skin adhesive. Approximately
three weeks later a tumor xenograft of 5 - 10 mm in
diameter developed. The mice were housed in transpar-
ent boxes with bedding material, fed ad libitum and
kept under specific pathogen-free conditions. The tem-
perature and relative humidity were kept constant at
20 - 21°C and 60%, respectively. At the end of the
experiments all mice were euthanized by cervical dislo-
cation. All procedures were performed according to pro-
tocols approved by the National Animal Research
Authority and carried out in compliance with the Eur-
opean Convention for the Protection of Vertebrates
Used for Scientific Purposes.
Radiotherapy
RT was delivered at a dose of 2 Gy/day for five consecutive
days (at experiment days 1 - 5) using a
60Co source
(Mobaltron 80, TEM instruments, Crawley, UK) with a
dose rate of 0.8 Gy/min. The mice were located in a cus-
tom designed vicryl tube with an opening for the tumor
bearing leg to be stretched out and fixated horizontally.
D u r i n gt h ep r o c e d u r eo n l yt h et u m o rb e a r i n gl e gw a s
extended into the radiation field, limiting radiation expo-
sure to the remaining body. The procedure was performed
under sedation induced by 0.05 ml of anesthetic agent.
Hypoxic radiotherapy
Tumor hypoxia was experimentally induced by placing the
mice in a vicryl tube. A rubber band was clamped around
the leg of the mouse, proximal to the xenograft. The rub-
ber band was left on for five minutes prior to and during
RT (at experiment days 1 - 5). During clamping the leg of
the mouse temporary turned bluish, indicating stagnation
of blood circulation with concurrent induction of acute
hypoxia. The discoloration disappeared rapidly following
removal of the rubber band and no mice became lame or
experienced any adverse effects from the clamping. The
procedure was performed under sedation induced by
0.05 ml of anesthetic agent.
PL-DXR
PL-DXR was administered at a dose of 3.5 mg DXR/kg
as a single i.v. bolus injection through the tail vein (at
experiment day 0). The rationale for using the relatively
low drug dose was to avoid reaching therapy saturation
levels where any additional effect produced by hypoxic
RT would not be detected.
Monitoring of treatment response
Mice bearing tumor xenografts sized 5 - 10 mm in dia-
meter were randomly allocated into different experimental
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experiment all mice were imaged by DCE MRI with subse-
quent i.v. administration of PL-DXR to mice designated to
the PL-DXR groups. RT treatment began 24 hrs later,
enabling sufficient time for liposomal tumor accumulation.
During daily RT sessions all mice, regardless of experi-
mental group, were sedated. To assess therapy-induced
changes in tumor vascular function all mice were sub-
jected to an identical imaging protocol 8 days after the
pre-treatment DCE MRI.
Tumor volumes were estimated after measuring the
tumors’ shortest and longest diameters with four days
intervals using a digital caliper (Model B220S, Kroeplin,
Schlüchtern, Germany). The tumor volume was calcu-
lated according to the formula (π/6)*length
2*width [25].
The tumor growth delay (TGD) in days for tumors to
reach a 3-fold increase in relative tumor volume, i.e.
treated tumors compared to control tumors; TGDV3,
was found for all experimental groups.
DCE MRI acquisitions
MRI acquisitions were performed as previously described
[26], using a 1.5 T GE Signa LS scanner (GE Medical Sys-
t e m s ,M i l w a u k e e ,W I ) ,a n dad e d i c a t e dM R Im o u s ec o i l
[27]. Prior to MRI, a heparinized 24G catheter attached to
a cannula containing 0.01 ml/g body weight contrast agent
(Dotarem
®, diluted in heparinized saline to 0.06 M) was
inserted into the tail vein of the mice. The mice were
placed in an adapted cradle and put into the coil, before
being placed in the scanner. During image acquisition, the
temperature of the mouse was maintained at 38°C. First,
the tumor was localized using axial fast spin-echo (FSE)
T2-weighted (T2W) images (echo time (TEeff)=8 5m s ,
repetition time (TR) = 4000 ms, echo train length (ETL) =
16, image matrix (IM) = 256 × 256, field-of-view (FOV) =
4 cm, slice thickness (ST) = 2 mm). Second, DCE MRI
was obtained with a dynamic fast spoiled gradient-recalled
(FSPGR) T1W sequence (TE = 3.5 ms, TR = 180 ms, IM
= 256 × 128, FOV = 6 cm, ST = 2 mm, and flip angle (FA)
= 80°). Following 5 baseline T1W image acquisitions, con-
trast kinetics were investigated by injecting the contrast
agent during 3 seconds and performing 20 minutes of
post-contrast imaging. The time resolution was 12 seconds
and the reconstructed voxel size was 0.23 × 0.23 × 2 mm
3.
DCE MRI analysis
Image analysis was performed using in-house developed
software in IDL (Interactive Data Language v 6.2,
Research Systems Inc., Boulder, CO). For the central
slice of each tumor, a region of interest (ROI) was
manually traced in T1W images, excluding surrounding
skin and connective tissue. The time-dependent relative
signal intensity, RSI(t), was calculated for each image
voxel according to Equation 1.
RSI(t)=
SI(t) − SI(0)
SI(0)
(1)
where SI(0) refers to the pre-contrast signal intensity
and SI(t) the post-contrast signal intensity in the voxel at
time t. To subsequently enable comparison of all tumors
in the experiment, it was ensured that all post-contrast
images were initiated after a 3 seconds injection of con-
trast agent. By using the MRI scanner’sr e c o r d e di m a g e
information any deviations from these 3 seconds could
be corrected by adjusting the time-axis of the post-con-
trast image set. Pharmacokinetic modeling was per-
formed using the Brix model [28], with the RSI(t) for
each voxel as input. The Brix model is a two-compart-
ment pharmacokinetic model where the contrast agent is
assumed to distribute between two individually well-
mixed compartments; the blood plasma and the extracel-
lular extravascular space (EES) in the tumor. The i.v.
injected contrast agent is transported into the tumor by
perfusion, where it diffuses between the plasma and the
EES, before being eliminated at a constant rate.
Using the RSI(t) for each voxel in the tumor ROI, the
Brix model (equation 2) was fitted using the Levenberg-
Marquardt least-squares minimization method (MPFIT;
http://purl.com/net/mpfit) [29].
RSI(t)=
Akep
kelkep
(e−kept − e−kelt) (2)
where the parameter kep i st h er a t ec o n s t a n tb e t w e e n
plasma and EES, kel the clearance rate of contrast agent
from plasma, and A an amplitude parameter related to
the size of the EES.
Immunohistochemistry of tumor hypoxia
In addition to the mice subjected to DCE MRI, parallel
groups of mice were followed to harvest tumor tissue at
t h es a m et i m e - p o i n ta st h ed a y8M R Ia c q u i s i t i o n s .
Mice designated to immunohistochemistry examination
received identical treatments as mice used for tumor
growth assessment and DCE MRI (Table 1), with each
group containing 8 tumors. Hypoxia was determined by
Table 1 Overview of treatments administered to the
different experimental groups
Experimental
groups
Treatment
Control No treatment
PL-DXR 3.5 mg DXR/kg (day 0)
PL-DXR +
hypoxic RT
3.5 mg DXR/kg (day 0) + clamping + 2 Gy/day for
5 days (day 1 - day 5)
RT 2 Gy/day for 5 days (day 1 - day 5)
Hypoxic RT Clamping + 2 Gy/day for 5 days (day 1 - day 5)
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[(2-hydroxy-3-piperidinyl)propyl]-2-nitroimidazole
hydrochloride, dissolved in saline i.p. One hour later
euthanasia was performed by cervical dislocation and
tumors were excised and preserved in phosphate-buf-
fered 4% formalin until tissue sectioning. Tumor
hypoxia was detected using a peroxidase-based immu-
nostaining method. In brief, tissue sections were stained
using the Dako EnVision™+ System-HRP (DAB)
(K4011) and Dakoautostainer. Deparaffinization and
unmasking of epitopes were performed using PT-Link
(DAKO) and EnVision™ Flex target retrieval solution,
with high pH. To block endogenous peroxidase, sections
were treated with 0.03% hydrogen peroxide for 5 min-
utes. The preparations were incubated 30 minutes with
polyclonal rabbit antibodies to pimonidazole-protein
adducts (1:10000 dilution). The sections were then incu-
bated with peroxidase-labeled polymer conjugated to
goat anti-rabbit secondary antibodies for 30 minutes.
T h et i s s u es e c t i o n sw e r es t a i n e df o r1 0m i n u t e sw i t h
3’3-diaminobenzidine tetrachloride (DAB) and counter-
stained with haematoxylin, dehydrated and mounted in
Diatex.
Statistical analysis
By means of a multiple regression procedure differences in
tumor growth between the experimental groups were
operationally represented by three between group compar-
isons; 1) comparing the RT group with the hypoxic RT
group, 2) comparing the RT group with the PL-DXR
group and finally, 3) comparing the hypoxic RT group
with the PL-DXR + hypoxic RT group. Tumor growth was
represented by linear and quadratic developmental trends.
Group differences in DCE MRI parameters and
hypoxic fractions were analyzed by student’s t-tests, and
the Pearson correlation (r)t e s ta n a l y z e dw h e t h e rc o r r e -
lations between variables were significant using SPSS
16.0 (SPSS, Cary, NC). A significance level of 5% was
used for all statistical analyses.
Results
Tumor growth
Tumor volume measurements were performed with four
days intervals for 29 days, except for the control group
where mice were euthanized at day 21 when the tumor
diameters exceeded 20 mm, i.e. in accordance with inter-
nal regulations for animal experiments. Based on the 21
days observation period, the tumor growth of the control
group was significantly faster compared to all treatment
groups (p < 0.050). The differences in tumor growth
between the remaining groups were analyzed on the basis
of the 29 days observation period. Based on quadratic
developmental trends the hypoxic RT group showed sig-
nificantly less therapeutic effect than the normoxic RT
group (comparison 1, p = 0.006). The group receiving
PL-DXR also presented significantly less therapeutic effect
than the RT group (comparison 2, p = 0.008). Interest-
ingly, tumor growth in the PL-DXR + hypoxic RT group
was significantly reduced compared to the hypoxic RT
group (comparison 3, p = 0.004). Tumor growth patterns
are portrayed in Figure 1. No adverse effects, including
skin toxicities, were observed in any of the experimental
groups.
Treatment monitoring using DCE MRI
Following Brix modeling of contrast kinetics, parametric
images of A, kel and kep were produced. The kep para-
meter is a parameter being estimated based on the initial
increase in the RSI curve, which is reflecting the in-wash
of contrast agent from plasma to EES. Due to these
tumors’ high permeability and/or high perfusion, this
initial increase was very steep, consequently precluding
the Brix model to reliably estimate mean tumor values of
kep for subsequent intra- and intergroup comparisons.
The kep parameters were therefore excluded. Also, due to
unsuccessful injection of contrast agent or technically
related issues, some of the tumors in the experiment
were excluded from subsequent pharmacokinetic analy-
sis. Further, some of the tumors were too small to enable
reliable DCE MRI analysis. The exact number of tumors
that underwent MRI and image analysis is indicated in all
relevant figures onwards.
In Figure 2, the mean group relative change in the A
parameter; an amplitude parameter related to the size of
the EES [28], from day 0 to day 8 is presented. A reduction
in the A parameter was observed for both the control
(18%) and the PL-DXR (26%, p = 0.030) groups. All
groups receiving radiation experienced a relative increase
from day 0 to day 8, being 4% in the PL-DXR + hypoxic
RT group (not significant), 20% (p = 0.002) in the hypoxic
RT group and 29% (p = 0.046) in the RT group. No signifi-
cant intergroup difference in the A parameter was
observed when comparing the control tumors with tumors
treated with PL-DXR. However, all groups receiving radia-
tion experienced a significant increase in the A parameter
compared to the control group; PL-DXR + hypoxic RT
(p = 0.019), hypoxic RT (p = 0.001) and RT (p = 0.006).
Additionally, the group receiving PL-DXR + hypoxic RT
also experienced an increase in the A parameter compared
to PL-DXR (p = 0.026) and a decrease compared to
hypoxic RT (p = 0.025) and RT (p = 0.049).
In Figure 3, the mean group relative change in the kel
parameter, reflecting the clearance rate of contrast agent
from plasma [28], from day 0 to day 8 is presented. Three
groups experienced an increase in kel, being 45% in the
control group, 85% in the PL-DXR group and 47% in
the PL-DXR + hypoxic RT group. Due to large intragroup
variations, these increases were not significant. Both the
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decrease in the kel parameter with the change in the
hypoxic RT group being significant (p = 0.007). No inter-
group differences in the kel parameter were observed when
comparing the control tumors with the tumors that
received PL-DXR or PL-DXR + hypoxic RT. However,
both the hypoxic RT group and the RT group experienced
significant reductions in the kel parameter compared to
the control group, (p = 0.015 and p = 0.020, respectively).
Immunohistochemistry of tumor hypoxia
Parallel to tumor growth and DCE MRI studies identically
treated groups of tumors were excised and used to assess
tumor hypoxia by performing pimonidazole immunohisto-
chemistry of tumor tissue excised at day 8, coinciding with
the time-point of post-treatment MRI acquisitions. Figure
4A presents the hypoxic fractions of the different experi-
mental groups. The mean hypoxic fractions were 23% for
the control tumors, 21% for tumors treated with PL-DXR
alone, 14% for the tumors receiving both PL-DXR and
hypoxic RT, 15% for tumors receiving hypoxic RT, and
11% for tumors receiving RT. Compared to the control
group, only the RT group presented significantly reduced
hypoxic fractions (p = 0.041). Figure 4B and 4C show
examples of pimonidazole staining in representative
untreated and irradiated tumors, respectively.
Correlations
Figure 5 shows the correlations between the mean group
hypoxic fractions at day 8 (%) versus the mean group
Figure 1 Tumor growth patterns for the experimental groups. Presented as mean ± SEM (n = 8 - 10 per group). The control group was
removed from the study at day 21 due to tumor diameters exceeding 20 mm (A). Tumor growth delays as mean number of days for tumors to
reach a 3-fold increase in relative tumor volume for each of the treatment groups versus the control group, TGDV3. *The RT group did not reach
3-fold increase in relative volume at day 29; thus the TGDV3 is more than 19 days (B).
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(%) (Figure 5A), the mean group relative change in the
kel parameter from day 0 to day 8 (%) (Figure 5B), and
the mean group relative change in tumor volumes from
day 0 to day 9 (%) (Figure 5C), respectively. The mean
group hypoxic fractions showed a strong negative corre-
lation to the mean group relative change in the A para-
meter from day 0 to day 8 (r = -0.93, p = 0.022), a
weaker and insignificant positive correlation to the
mean group relative change in the kel parameter from
day 0 to day 8 (r = 0.74, p = 0.155), and a positive cor-
relation to the mean group tumor volume change from
day 0 to day 9 (r = 0.94, p = 0.019).
Figure 6 shows the correlations between the mean
group relative change in tumor volumes from day 0 to
day 9 (%) versus the mean group relative change in the
A parameter from day 0 to day 8 (%) (Figure 6A) and
the mean group relative change in the kel parameter
from day 0 to day 8 (%) (Figure 6B), respectively. Mean
group tumor volume change correlated negatively to the
mean group relative change in the A parameter (r =
-0.91, p = 0.030) from day 0 to day 8, and positively, but
not significantly, to the mean group relative change in
the kel parameter (r = 0.75).
Discussion
Tumor hypoxia prevent effective RT [3-5], and several
strategies to improve RT efficacy under hypoxic condi-
tions have been described [6,7]. The ability of PL-DXR
to enhance the therapeutic effect of fractionated and
single dose RT has previously been reported [19,21]. In
the current study we demonstrated that PL-DXR
improves the therapeutic effect of RT also under
hypoxic conditions. Moreover, as it is important to
develop strategies to monitor treatment responses non-
invasively, DCE MRI appears to be promising for this
purpose.
The current PL-DXR formulation accumulates slowly
in tumors, reaching peak levels 2-3 days post injection
in tumor xenograft models [30,31]. Consequently, sub-
stantial levels of PL-DXR in the tumors during the five
days of RT were expected. Any RT-mediated changes in
tumor vascular functions that could interfere with
tumor liposome accumulation was expected to be mini-
mal as RT previously has reported to not alter liposomal
tumor uptake [32,33].
Free DXR is reported to decrease tumor blood flow
[34,35], subsequently reducing the oxygen levels in
tumors. In contrary, PL-DXR has been suggested to nor-
malize tumor vasculature [36]. In the current study there
was no significant difference between the control and the
PL-DXR group in any of the DCE MRI derived kinetic
parameters or hypoxic fractions, suggesting that PL-DXR
did not alter vascular functions. Still, tumor growth was
significantly inhibited indicating that PL-DXR may exert
tumoricidal effects without interfering with tumor blood
circulation. This feature is highly beneficial with respect
Figure 2 Relative change in the A parameter (mean ± SEM)
from day 0 to day 8 for the experimental groups. 3.5 mg/kg PL-
DXR was administered after pre-treatment DCE MRI. RT was
delivered at a dose of 2 Gy/day for 5 consecutive days, starting 24
hours after the pre-treatment DCE MRI. Hypoxia was induced by
clamping the tumor-bearing leg 5 minutes prior to and during RT.
Significant differences (p < 0.050) to the control or PL-DXR +
hypoxic RT groups are indicated with # or ×, respectively.
Figure 3 Relative change in the kel parameter (mean ± SEM)
from day 0 to day 8 for the experimental groups. 3.5 mg/kg PL-
DXR was administered after pre-treatment DCE MRI. RT was
delivered at a dose of 2 Gy/day for 5 consecutive days, starting 24
hours after pre-treatment DCE MRI. Hypoxia was induced by
clamping the tumor-bearing leg 5 minutes prior to and during RT.
Significant differences (p < 0.050) to the control or PL-DXR +
hypoxic RT groups are indicated with # or ×, respectively.
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tumors more likely respond better to RT.
In contrary, RT induced changes in the tumor vascula-
ture both in the hypoxic and normoxic tumors, as mea-
sured by an increase in the A parameter. This alternation
may be related to an increased interstitial volume, and a
reduced elimination rate of contrast agent, as indicated
by the kel parameter. The increase seen in the A para-
meter may be related to radiation-induced necrosis and/
or edema, and thus increased interstitial volume. Further,
an increase in the A parameter may reflect disrupted
membranes increasing the extracellular volume due to
elevated membrane permeability. Finally, the observed
reductions in the kel parameter may reflect radiation-
induced endothelial cell death, making clearance of con-
trast agent less effective. Interestingly, when hypoxic RT
was administered in combination with PL-DXR these
changes became less evident, indicating that PL-DXR
reduced some of the vascular effects caused by RT in
hypoxic tumors.
Based on the pharmacokinetic theory behind the Brix
model the amplitude parameter A is related to the size
o ft h eE E S[ 2 8 ] .H e r ew es h o wt h a tt h ec h a n g e si nt h e
A parameter from day 0 to day 8 were significantly cor-
related to tumor hypoxic fractions (Figure 5A). A similar
relation has also been found in a clinical DCE MRI
study of cervical cancer, where a positive correlation
between the A parameter and oxygen levels, as mea-
sured by Eppendorf pO2 histography, was evidenced
[37]. This may suggest the A parameter as a candidate
biomarker of tumor hypoxia, for further investigation.
The kel parameter is theoretically reflecting the clearance
rate of contrast agent from plasma [28], which is
affected by the functionality of the tumor vasculature.
Compared to the A parameter, our results showed that
the kel parameter correlated less to hypoxia (Figure 5B).
However, hypoxic fractions correlated significantly (Fig-
ure 5C) with tumor volume changes and may explain
why the measured hypoxic fractions were highest in the
control tumors and lowest in the tumors receiving the
most effective treatments. Hypoxia and tumor size have
also previously been demonstrated to correlate strongly
[38].
During the last years, several imaging modalities have
been investigated for their possible ability to provide non-
invasive biomarkers of tumor hypoxia. If such biomarkers
can be identified and validated, they are likely to provide
important consequences in personalized cancer treatment,
for example in detection of treatment-resistant tumors
requiring alternative therapeutic strategies, for delivering
Figure 4 Hypoxic fractions in the experimental groups at day 8 assessed from pimonidazole immunohistochemistry of tumor tissue
sections. Group mean and SEM are shown, with n = 8 per group. 3.5 mg/kg PL-DXR was administered 24 hours prior to RT. RT was delivered at
a dose of 2 Gy/day for 5 consecutive days. Hypoxia was induced by clamping the tumor-bearing leg 5 minutes prior to and during RT. A
significant difference (p < 0.05) to the control group is indicated with # (A). Representative images of pimonidazole-stained sections of an
untreated tumor (B), and an irradiated tumor (C), respectively.
Hagtvet et al. Radiation Oncology 2011, 6:135
http://www.ro-journal.com/content/6/1/135
Page 7 of 10intensified radiotherapy to hypoxic tumor regions, and as a
means to monitor the response to therapies. In this
respect, particularly positron emission tomography (PET)
using various radiotracers aiming to detect tumor hypoxia
[39], and DCE MRI [40], are clinically feasible and promis-
ing tools which have been employed in preclinical and
clinical studies. However, the potential of providing more
quantitative measures by applying pharmacokinetic mod-
els in data analysis is currently less investigated,
warranting further studies. The benefits of using MRI
compared to PET are particularly the avoidance of ioniz-
ing radiation exposure and injection of radioactive sources,
as well as being a more cost-effective imaging modality.
The treatment-induced changes in the A parameter
correlated significantly and negatively to tumor volume
changes (Figure 6A), and changes in the kel parameter
correlated strongly and positively, although not signifi-
c a n t l y ,t ot h e s ev o l u m ec h anges (Figure 6B). This is
Figure 5 Hypoxic fractions versus DCE MRI parameters and tumor volumes. Correlations between the mean group hypoxic fractions (%) at
day 8 versus the mean group relative change in the A parameter from day 0 to day 8 (%) (A), the mean group relative change in the kel
parameter from day 0 to day 8 (%) (B), and the relative change in mean group tumor volumes from day 0 to day 9 (%) (C), respectively.
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pharmacokinetic image analysis as tools for non-invasive
monitoring of therapeutic effects.
T h ep r e s e n c eo fo x y g e ni nt u m o r se x p o s e dt oR Ti s
crucial because oxygen 1) enhance the yield of radia-
tion-induced radicals and thus DNA damage, and 2)
prevent repair of induced DNA damage by fixation of
the damage [41]. DXR enhances the therapeutic effect of
RT presumably by preventing cells from repairing radia-
tion-induced DNA damage [11-13]. DXR may therefore
resemble the effect of oxygen in tumors exposed to RT.
Hypoxia is a common feature amongst most solid, clini-
cal tumors [42]. Overcoming hypoxia by administration
of radiosensitizing drugs may nevertheless be of limited
success as their supply to hypoxic regions commonly
are hampered by inadequate vascularization. Liposomal
DXR seems however to have a positive effect on the
tumor vascular functions as shown in this study.
Conclusion
The present study shows that PL-DXR improves the thera-
peutic effect of RT under hypoxic conditions and that PL-
DXR does not affect tumor vascular functions. Interest-
ingly, PL-DXR appeared to reduce some of the vascular
alterations induced in hypoxic tumors by RT. Hence, for
drugs that affect tumor vascular functions liposomes may
be a promising drug delivery technology for use in CRT.
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